Dr. Amelia T. Murphy
Founder of Nova Biosciences. Co-author (with Dr. Mark Lee Spencer) of the 2110 TIGR-Tas paper — a nanoscale gene-editing delivery platform that achieved 100% clinical clearance of prion, Huntington’s, and amyloid-associated neurodegeneration in trial. The platform was not commercialized; Earth-side health systems already had cheaper, established standard-of-care treatments for all three conditions.
Moved from Dome 1 to Dome 4 around 2118, redirecting the TIGR-Tas platform toward space radiation damage repair — a market with no existing competitors. During extended trials, the redesigned platform demonstrated an unplanned anti-aging effect: telomere elongation and partial reversal of age-associated DNA methylation patterns. Resigned her UN research post to accept Omani private capital and found Nova Biosciences, developing the platform as Project Prometheus.
Gave a public interview to Luna Interplanetary News in 2124 explaining the platform’s origin, the commercial failure of the original neurodegenerative application, and the unplanned anti-aging discovery.